AIXC Key Statistics, Chart & Performance
The current stock price of AIXC is 2.51 USD.
AIXC Latest News, Press Relases and Analysis
AIXC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About AIXC
Company Profile
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Company Info
AIXCRYPTO HOLDINGS INC
2042 Corte Del Nogal
Carlsbad CALIFORNIA US
Employees: 4
Phone: 17609189165
AIXCRYPTO HOLDINGS INC / AIXC FAQ
Can you describe the business of AIXCRYPTO HOLDINGS INC?
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
What is the stock price of AIXCRYPTO HOLDINGS INC today?
The current stock price of AIXC is 2.51 USD. The price decreased by -0.79% in the last trading session.
What is the dividend status of AIXCRYPTO HOLDINGS INC?
AIXC does not pay a dividend.
What is the ChartMill rating of AIXCRYPTO HOLDINGS INC stock?
AIXC has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of AIXCRYPTO HOLDINGS INC (AIXC)?
AIXCRYPTO HOLDINGS INC (AIXC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.59).
Is AIXCRYPTO HOLDINGS INC (AIXC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AIXC.
AIXC Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AIXC.
AIXC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AIXC. The financial health of AIXC is average, but there are quite some concerns on its profitability.
AIXC Financial Highlights
Over the last trailing twelve months AIXC reported a non-GAAP Earnings per Share(EPS) of -8.59. The EPS increased by 84.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.62% | ||
| ROE | -21% | ||
| Debt/Equity | 0.08 |
AIXC Forecast & Estimates
For the next year, analysts expect an EPS growth of 62.96% and a revenue growth -100% for AIXC